Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab by Meng Wu, Claudia A.M. Fulgenzi, Antonio D’Alessio, Alessio Cortellini, Ciro Celsa, Giulia F. Manfredi, Bernardo Stefanini, Y. Linda Wu, Yi-Hsiang Huang, Anwaar Saeed, Angelo Pirozzi, Tiziana Pressiani, Lorenza Rimassa, Martin Schoenlein, Kornelius Schulze, Johann von Felden, Yehia Mohamed, Ahmed O. Kaseb, Arndt Vogel, Natascha Roehlen, Marianna Silletta, Naoshi Nishida, Masatoshi Kudo, Caterina Vivaldi, Lorenz Balcar, Bernhard Scheiner, Matthias Pinter, Amit G. Singal, Joshua Glover, Susanna Ulahannan, Fredrich Foerster, Arndt Weinmann, Peter R. Galle, Neehar D. Parikh, Wei-Fan Hsu, Alessandro Parisi, Hong Jae Chon, David J. Pinato, Celina Ang

“…On multivariate Cox regression analysis, absence of portal vein tumor thrombus, ECOG <2, and continued active treatment were predictors of better PPS. mPPS was significantly longer for patients who continued active treatment vs. …”
Get full text

LGR4 is essential for maintaining β-cell homeostasis through suppression of RANK by Joanna Filipowska, Zelda Cisneros, Sneha S. Varghese, Nancy Leon-Rivera, Peng Wang, Randy Kang, Geming Lu, Yate-Ching Yuan, Hung-Ping Shih, Supriyo Bhattacharya, Sangeeta Dhawan, Adolfo Garcia-Ocaña, Nagesha Guthalu Kondegowda, Rupangi C. Vasavada

“…Mechanistically, LGR4 protects β-cells by suppressing RANK- Tumor necrosis factor receptor associated factor 6 (TRAF6) interaction and subsequent activation of NFκB. …”
Get full text

Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y glo... by Mieke Van Hemelrijck, Salvatore Grisanti, Avinash Aujayeb, Martin Forster, Giannis Mountzios, Andrea Napolitano, Bruno Vincenzi, Joachim G J V Aerts, Marina Garassino, Valter Torri, Solange Peters, Alex Friedlaender, Alfredo Addeo, Giuseppe Lo Russo, Roberto Ferrara, Diego Signorelli, Alessandro Russo, So Yeon Kim, Jarushka Naidoo, Scott Gettinger, Heather Wakelee, Martin Sebastian, Mark Awad, Abdul Rafeh Naqash, Alessio Cortellini, Raffaele Giusti, Michele De Tursi, Federica Zoratto, Marco Russano, Rita Chiari, Biagio Ricciuti, Andrea De Giglio, Alain Gelibter, Giuseppe Tonini, Amin H Nassar, Alessandra Curioni-Fontecedro, Eleni Karapanagiotou, Emilio Bria, Jack Bell, Paolo Bironzo, Joao V Alessi, Alessandro Morabito, David J Pinato, Francesco Passiglia, Carlo Genova, Francesca Mazzoni, Alessandro Inno, Francesco Grossi, Luca Cantini, Lorenza Landi, Luigi Della Gravara, Margarita Majem, Uma Mukherjee, Federica Biello, Alessandro Leonetti, Annalisa Guida, Marianna Macerelli, Gabriele Minuti, Giulio Metro, Thomas Newsom-Davis, Eleni Josephides, Andrea Camerini, Elisa Roca, David O’Reilly, Mingjia Li, Laura Mezquita, Teresa Gorría, Claudia A M Fulgenzi, Lauren Young, Joel W Neal, Javier Baena, Francesco Pantano, Jacobo Rogado, Mary Jo Fidler, Teresa Beninato, Federica Pecci, Alessandro Di Federico, Kazuki Takada, Leonardo Brunetti, Talal El Zarif, Laura Moliner, Alberto Servetto, Sukumar Kalvapudi, Sai Yendamuri, Edoardo Garbo, Giuseppina Rita Di Fazio, Monica Loza, Ritujith Jayakrishnan, Michele Montrone, Nichola O Awosika, Bartlomiej Tomasik, Maximilian Rost, Isabelle Monnet, Francesco Agustoni, Artur Katz, Dwight Hall Owen, Michele Ghidini, Armida D’Incecco, Gianpaolo Spinelli, Monica Verrico, Manuel Dupont, Rafael Di Marco Barros, Diego Luigi Cortinovis, Chiara Bennati, Frank Aboubakar Nana, Anne-Marie Dingemans, Taher Abu Hejleh

“…Background Pembrolizumab monotherapy is an established front-line treatment for advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) tumor proportion score (TPS)≥50%. However, real-world data on its long-term efficacy remains sparse.Methods This study assessed 5-year outcomes of first-line pembrolizumab monotherapy in a large, multicenter, real-world cohort of patients with advanced NSCLC and PD-L1 TPS≥50%, referred to as Pembro-real 5Y. …”
Get full text

Comparative evaluation of multimarker algorithms for early-stage HCC detection in multicenter prospective studies by Jinlin Hou, Thomas Berg, Arndt Vogel, Teerha Piratvisuth, Jörg Trojan, Enrico N. De Toni, Masatoshi Kudo, Katarina Malinowsky, Peter Findeisen, Johannes Kolja Hegel, Wenzel Schöning, Kairat Madin, Konstantin Kroeniger, Henry Lik-Yuen Chan, Ashish Sharma

“…The GAAD and GALAD algorithms demonstrated similar good performance regardless of disease etiology, presence of cirrhosis, geographical region, and within pan-tumor specificity panels (p <0.001). Conclusions: GAAD (Cobas) demonstrated good clinical performance, similar to GALAD (Cobas and μTASWAKO) algorithms, in differentiating HCC and CLD controls, across all disease stages, etiologies, and regions; therefore, AFP-L3 may have a negligible role in GALAD for HCC surveillance. …”
Get full text

Uptake and hesitancy of the second booster dose of COVID-19 vaccine among the general population in China after the surge period of the COVID-19 pandemic: a large-scale national st... by Xin Liu, You Xin, Ling Zhang, Yijin Wu, Shu Jing, Zhenwei Dai, Tianrui Ren, Xiaoyang Liu, Jiaqi Fu, Xu Chen, Weijun Xiao, Hao Wang, Yiman Huang, Wenjun Wang, Xiaofen Gu, Li Ma, Shaokai Zhang, Yanqin Yu, Li Li, Tianzuo Gao, Tianyou Zhao, Yimin Qu, Xinyan Liu, Xiaoyou Su, Youlin Qiao

Get full text

Surgeons are apprehensive to use DCD lungs despite similar post-transplant outcomes: A 20-year UNOS retrospective analysis by J. Sam Meyer, MSc, Oliver K. Jawitz, MD, MHS, Yury Peysakhovich, MD, Dan Aravot, MD, Matthew G. Hartwig, MD, MHS, Yaron D. Barac, MD, PhD

“…A multivariable regression analysis showed that the odds of a potential DCD donating lungs is 75% lower than (P < 0.001) that of a potential DBD when the cause of death (COD) is stroke, head trauma (44% lower P = 0.076), CNS tumor (22% lower P = 0.174) or MVA (69% lower P = 0.183). …”
Get full text

Safety and efficacy of low-dose esketamine weakly opioidized anesthesia in elderly patients with lumbar spinal stenosis undergoing surgery: a prospective, double-blind randomized c... by Ni-Na Hou, Meng-Yun Zhang, Yu-Wei Zhang, Hong-Jing Wu, Hong Luo, Heng Yang

“…Pain (VAS rest and movement scores) on preoperative day 1 (POD-1), postoperative day 1 (POD1), postoperative day 3 (POD3), and postoperative day 7 (POD7), and serum levels of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), and interleukin-10 (IL-10) on POD-1, POD1, POD3, and POD7 were the secondary outcomes. …”
Get full text

Comparative Analysis of the Outcomes of Laparoscopic Right Hemicolectomy with D2 and D3 Lymphadenectomy in the Treatment of Patients with Right Colon Cancer by A. A. Nevolskikh, V. A. Avdeenko, Yu. Yu. Mikhaleva, T. P. Pochuev, P. V. Sokolov, R. F. Zibirov, I. P. Reznik, N. D. Silin, L. O. Petrov, S. A. Ivanov, A. D. Kaprin

“…When assessing the homogeneity and comparability of the groups, according to input parameters, such as clinical stage, gender, age, body mass index and tumor location, their heterogeneity was noted, which did not allow a direct comparative assessment of both groups. …”
Get full text

The prognosis and metabolite changes of NSCLC patients receiving first‐line immunotherapy combined chemotherapy in different M1c categories according to 9th edition of TNM classifi... by Liang Zheng, Fang Hu, Wei Nie, Jun Lu, Bo Zhang, Jianlin Xu, Shuyuan Wang, Ying Li, Xiaoxuan Zheng, Wei Zhang, Yinchen Shen, Runbo Zhong, Tianqing Chu, Baohui Han, Hua Zhong, Xueyan Zhang

“…These changes predominantly involved alterations in lipid metabolism, such as decreased diacylglycerol and sphingomyelin, which may impact tumor migration and invasion.…”
Get full text

Application of cellular microstructural diffusion MRI (cell size imaging) in rectal lesions: a preliminary study by Peisi Kou, Liangjie Lin, Ying Li, Hui Qin, Kun Zhang, Wenhua Zhang, Juan Li, Yong Zhang, Jingliang Cheng

“…In AC group, the dmean had significant difference between negative and positive tumor budding (TB) ([13.2590 ± 1.3255 μm] vs. [14.3014 ± 1.1830 μm], P&lt;0.05). …”
Get full text

Phase I study of intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or ade... by Lucie Heinzerling, Michael Fluck, Caroline Robert, Celeste Lebbe, Erika Richtig, Sven D Koch, Ulrike Gnad-Vogt, Tobias Seibel, Thomas Eigentler, Juan Martin-Liberal, Sebastian Ochsenreither, Peter Mohr, Patrick Terheyden, Carsten Weishaupt, Michael Erdmann, Lukas Koch, Ainara Soria, Igor Samoylenko, Jürgen Krauß, Peter Brossart, Franz Georg Bauernfeind, Marina Gonzalez, Peter Wengenmayer, Ioannis Thomas, Artem Poltoratskiy, Marina Sekacheva, Beate Schmitt-Bormann, Gianluca Quintini, Martin Falk, Paula Codó, Arjun Oberoi, Jana Hess, Yulia Semiletova, Casilda Llacer Perez, Oliver Schönborn-Kellenberger

Get full text

Midostaurin shapes macroclonal and microclonal evolution of FLT3-mutated acute myeloid leukemia by Romane Joudinaud, Augustin Boudry, Laurène Fenwarth, Sandrine Geffroy, Mikaël Salson, Hervé Dombret, Céline Berthon, Arnaud Pigneux, Delphine Lebon, Pierre Peterlin, Simon Bouzy, Pascale Flandrin-Gresta, Emmanuelle Tavernier, Martin Carre, Sylvie Tondeur, Lamya Haddaoui, Raphael Itzykson, Sarah Bertoli, Audrey Bidet, Eric Delabesse, Mathilde Hunault, Christian Récher, Claude Preudhomme, Nicolas Duployez, Pierre-Yves Dumas

Get full text

Deep learning helps discriminate between autoimmune hepatitis and primary biliary cholangitis by Alessio Gerussi, Oliver Lester Saldanha, Giorgio Cazzaniga, Damiano Verda, Zunamys I. Carrero, Bastian Engel, Richard Taubert, Francesca Bolis, Laura Cristoferi, Federica Malinverno, Francesca Colapietro, Reha Akpinar, Luca Di Tommaso, Luigi Terracciano, Ana Lleo, Mauro Viganó, Cristina Rigamonti, Daniela Cabibi, Vincenza Calvaruso, Fabio Gibilisco, Nicoló Caldonazzi, Alessandro Valentino, Stefano Ceola, Valentina Canini, Eugenia Nofit, Marco Muselli, Julien Calderaro, Dina Tiniakos, Vincenzo L’Imperio, Fabio Pagni, Nicola Zucchini, Pietro Invernizzi, Marco Carbone, Jakob Nikolas Kather

Get full text